低分化和间变性甲状腺癌：基因组学、微环境及新药研究进展

Poorly Differentiated and Anaplastic Thyroid Cancer: Insights into Genomics, Microenvironment and New Drugs.

作者信息

Prete Alessandro, Matrone Antonio, Gambale Carla, Torregrossa Liborio, Minaldi Elisa, Romei Cristina, Ciampi Raffaele, Molinaro Eleonora, Elisei Rossella

机构信息

Endocrine Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Via Paradisa 2, 56124 Pisa, Italy.

Department of Surgical, Medical, Molecular Pathology and Critical Area, University Hospital of Pisa, 56124 Pisa, Italy.

出版信息

Cancers (Basel). 2021 Jun 26;13(13):3200. doi: 10.3390/cancers13133200.

DOI:10.3390/cancers13133200

PMID:34206867

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8267688/

Abstract

PDTC and ATC present median overall survival of 6 years and 6 months, respectively. In spite of their rarity, patients with PDTC and ATC represent a significant clinical problem, because of their poor survival and the substantial inefficacy of classical therapies. We reviewed the newest findings about genetic features of PDTC and ATC, from mutations occurring in DNA to alterations in RNA. Therefore, we describe their tumor microenvironments (both immune and not-immune) and the interactions between tumor and neighboring cells. Finally, we recapitulate how this upcoming evidence are changing the treatment of PDTC and ATC.

摘要

乳头状微小癌（PDTC）和甲状腺未分化癌（ATC）的中位总生存期分别为6年和6个月。尽管它们较为罕见，但PDTC和ATC患者却是一个重大的临床问题，因为其生存率低，且传统疗法疗效甚微。我们回顾了有关PDTC和ATC基因特征的最新研究结果，从DNA发生的突变到RNA的改变。因此，我们描述了它们的肿瘤微环境（包括免疫和非免疫微环境）以及肿瘤与邻近细胞之间的相互作用。最后，我们总结了这些新出现的证据如何正在改变PDTC和ATC的治疗方式。